Liposomal drug formulations: Rationale for development and what we can expect for the future

Drugs

Volumn 56, Issue 5, 1998, Pages 747-756

  Allen, Theresa M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACID; ANTHRACYCLINE; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BASE; CREMOPHOR; DAUNORUBICIN; DOXORUBICIN; DRUG CARRIER; EXCIPIENT; LIPOSOME; MACROGOL; PHOTOSENSITIZING AGENT; PROPYLENE GLYCOL; TUMOR NECROSIS FACTOR ALPHA;

BLOOD BRAIN BARRIER; CARDIOTOXICITY; DRUG COST; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; INHALATIONAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MULTIDRUG RESISTANCE; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW; SKIN EXFOLIATION; SOLID TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION; SUSTAINED RELEASE FORMULATION; TOPICAL DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0031729149     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199856050-00001     Document Type: Review

References (76)

1. Allen TM. Liposomal drug delivery. Curr Opin Colloid Interface Sci 1996; 1: 645-51
2. Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm 1997; 154: 123-40
3. Casper ES, Schwartz GK, Sugarman A, et al. Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma. J Clin Oncol 1997; 15 (5): 2111-7
4. Muggia F, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987-93
5. Ranson M, Howell A, Cheeseman S, et al. Liposomal drug delivery. Cancer Treat Rev 1996; 22: 365-79
6. Woodle MC, Storm G, editors. Long-circulating Liposomes: old drugs, new therapeutics. Georgetown (TX): Landes Bioscience, 1998
7. Wasan KM, Lopez-Berenstein G. The past, present and future uses of liposomes in treating infectious diseases. Immunopharmacol Immunotoxicol 1995; 17: 1-15
8. Abraham E, Park YC, Covington P, et al. Liposomal prostaglandin E(1) in acute respiratory distress syndrome: a placebo-controlled, randomized, double-blind, multicenter clinical trial. Crit Care Med 1996; 24 (1): 10-5
9. Deol P, Khuller GK. Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim Biophys Acta 1997; 1334: 161-72
10. Dipali SR, Lin Y-J, Ravis WR, et al. Pharmacokinetics and tissue distribution of long circulating liposomal formulation of 2′,3′ dideoxyinosine. Int J Pharm 1997; 152: 89-97
11. Defrise-Quertain F, Chatelain P, Delmelle M, et al. Model studies for drug entrapment and liposome stability. In: Gregoriadis G, editor. Liposome technology. Vol. 2. 1st ed. Boca Raton (FL): CRC Press Inc., 1984: 1-17
12. Allen TM, Mehra T, Hansen CB, et al. Stealth liposomes: an improved sustained release system for 1-β-D-arabinofuranosylcytosine. Cancer Res 1992; 52: 2431-9
13. Perez-Soler R, Francis K, al-Baker S, et al. Preparation and characterization of liposomes containing a lipophilic cisplatin derivative for clinical use. J Microencapsul 1994; 11 (1): 41-54
14. Perez-Soler R, Neamati N, Zou Y, et al. Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide. Int J Cancer 1997; 71: 35-41
15. Perez-Soler R, Shin DM, Siddik ZH, et al. Phase I clinical and pharmacological study of liposome-entrapped NPDP administered intrapleurally in patients with malignant pleural effusions. Clin Cancer Res 1997; 3: 373-9
16. Haran G, Cohen R, Bar LK, et al. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993; 1151: 201-15
17. Cullis PR, Hope MJ, Bally MB, et al. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar liposomes. Biochim Biophys Acta 1997; 1331: 187-211
18. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 987-92
19. Cevc G, editor. Phospholipids handbook. New York (NY): Marcel Dekker Inc., 1993
20. Sharma A, Straubinger RM. Novel taxol formulations, preparation and characterization of taxol-containing liposomes. Pharm Res 1994; 11: 889-96
21. Bernard E, Dubois J-L, Wepierre J. Importance of sebaceous glands in cutaneous penetration of an antiandrogen: target effect of liposomes. J Pharm Sci 1997; 86: 573-8
22. Reddi E. Role of delivery vehicle for photosensitizers in the photodynamic therapy of tumours. J Photochem Photobiol 1997; 37: 189-95
23. Borsa J, Whitmore GF, Valeriote FA, et al. Studies on the persistence of methotrexate, cytosine arabinoside, and leucovorin in serum of mice. J Natl Cancer Inst 1969; 42 (2): 235-42
24. Burke TG, Gao X. Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine. J Pharm Sci 1994; 83 (7): 967-9
25. 't Hart BA, Elferink DG, Frijfhout JW, et al. Liposome-mediated peptide loading of MHC-DR molecules in vivo. FEBS Lett 1997; 409: 91-5
26. ten Hagen TLM, Eggermont AMM. A rat extremity soft tissue sarcoma model for the study of systemic treatment with Stealth liposome-encapsulated tumor necrosis factor-α and cytotoxic agents. Adv Drug Del Rev 1997; 24: 245-56
27. Khanna C, Anderson PM, Hasz DE, et al. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer 1997; 79: 1409-21
28. Allen TM. A study of phospholipid interactions between high-density lipoproteins and small unilamellar vesicles. Biochim Biophys Acta 1981; 640: 385-97
29. Scherphof GL, Damen J, Wilschut, J. Interactions of liposomes with plasma proteins. In: Gregoriadis G, editor. Liposome technology. Vol. 2. 1st ed. Boca Raton (FL): CRC Press, 1984: 205-24
30. Wasan KM, Morton RE. Differences in lipoprotein concentration and composition modify the plasma distribution of free and liposomal annamycin. Pharm Res 1996; 13: 462-8
31. Horowitz AT, Barenholz Y, Gabizon AA. In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. Biochim Biophys Acta 1992; 1109: 203-9
32. Allen TM, Newman MS, Woodle MC, et al. Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. Int J Cancer 1995; 62: 199-204
33. Lim HJ, Masin D, Madden TD, et al. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. J Pharmacol Exp Ther 1997; 281: 566-73
34. Chu CJ, Szoka C. pH-sensitive liposomes. J Liposome Res 1991; 4: 361-95
35. Srinath P, Jain NK. Signal sensitive liposomes. Indian Drugs 1994; 31 (7): 284-90
36. Boman NL, Masin D, Mayer LD, et al. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res 1994; 54: 2830-3
37. Kirpotin D, Hong K, Mullah N, et al. Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol). FEBS Lett 1996; 388: 115-8
38. Wu NZ, Braun RD, Gaber MH, et al. Simultaneous measurement of liposome extravasation and content release in tumors. Microcirculation 1997; 4 (1): 83-101
39. Thierry AR, Vige D, Couglin SS, et al. Modulation of doxorubicin resistance in multidrug resistant cells by liposomes. FASEB J 1993; 7: 572-9
40. Sharma A, Mayhew E, Straubinger RM. Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model. Cancer Res 1993; 53 (24): 5877-81
41. Suzuki S, Inoue K, Hongoh A, et al. Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferrin receptor. Br J Cancer 1997; 76 (1): 83-9
42. Pecheur El, Hoekstra D, Sainte-Marie J, et al. Membrane anchorage brings about fusogenic properties in a short synthetic peptide. Biochemistry 1997; 36: 3773-81
43. Hwang KJ. Liposome pharmacokinetics. In: Ostro MJ, editor. Liposomes: from biophysics to therapeutics. New York (NY): Marcel Dekker, 1987: 109-56
44. Allen TM, Hansen CB, Lopes de Menezes DE. Pharmacokinetics of long circulating liposomes. Adv Drug Del Rev 1995; 16: 267-84
45. Scherphof GL, Velinova M, Kamps J, et al. Modulation of pharmacokinetic behavior of liposomes. Adv Drug Del Rev 1997; 24: 179-91
46. Alving CR, Steck EA, Chapman WLJ, et al. Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. Proc Natl Acad Sci U S A 1978; 75 (6): 2959-63
47. Allen TM. The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system. Adv Drug Del Rev 1194; 13: 285-309
48. Torchilin VP, Trubetskoy VS. Use of polyoxyethylene-lipid conjugates as long-circulating carriers for delivery of therapeutic and diagnostic agents. Adv Drug Del Rev 1995; 16: 141-55
49. Ceh B, Winterhalter M, Frederik PM, et al. Stealth liposomes: from theory to product. Adv Drug Del Rev 1997; 24: 165-77
50. Mezei M. Liposomes and the skin. In: Gregoriadis G, Florence AT, Patel MH, editors. Liposomes in drug delivery. Yverdon, Switzerland: Harwood Academic, 1993: 125-35
51. Cevc G. Transfersomes, liposomes and other lipid suspensions on the skin: permeation, enhancement, vesicle penetration, and transdermal drug delivery. Crit Rev Ther Drug Carrier Syst 1996; 13: 257-388
52. Young AM, Gregoriadis G. Photolysis of retinol in liposomes and its protection with tocopherol and oxybenzone. Photochem Photobiol 1996; 63 (3): 344-52
53. Chen H, Langer R. Magnetically-responsive polymerized liposomes as potential oral delivery vehicles. Pharm Res 1997; 14 (4): 537-40
54. Kakinuma K, Tanaka R, Takahashi H, et al. Targeting chemotherapy for malignant brain tumor using thermosensitive liposome and localized hyperthermia. J Neurosurg 1996; 84 (2): 180-4
55. Siegal T, Horowitz A, Gabizon A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurgery 1995; 83 (6): 1029-37
56. Khalifa A, Dodds D, Rampling R, et al. Liposomal distribution in malignant glioma: possibilities for therapy. Nucl Med Commun 1997; 18: 17-23
57. Boman NL, Tron VA, Bally MB, et al. Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes. Cancer Chemother Pharmacol 1996; 37 (4): 351-5
58. Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995; 13: 1777-85
59. Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol; pharmacokinetics, tumour localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 1996; 36: 55-63
60. Forssen EA. The design and development of DaunoXome® for solid tumor targeting in vivo. Adv Drug Del Rev 1997; 24: 133-50
61. Allen TM. Toxicity of drug carriers to the mononuclear phagocyte system. Adv Drug Del Deliv 1988; 2: 55-67
62. Parr MJ, Bally MB, Cullis PR. The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade. Biochim Biophys Acta 1993; 1168: 239-52
63. Amantea MA, Forrest A, Northfelt DW, et al. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. Clin Pharmacol Therap 1997; 61 (3): 301-11
64. Goebel F-D, Goldstein D, Goos M, et al. Efficacy and safety of Stealth® liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Br J Cancer 1996; 73: 989-44
65. Wu NZ, Da D, Rudoll TL, et al. Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumour tissue. Cancer Res 1993; 53: 3765-70
66. Bakker-Woudenberg IAJM, Storm G, Woodle MC. Liposomes in the treatment of infections. J Drug Target 1994; 2: 363-71
67. Unezaki S, Maruyama K, Hosoda J-I, et al. Direct measurement of the extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy. Int J Pharm 1996; 144: 11-7
68. Gabizon A, Goren D, Horowitz AT, et al. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv Drug Del Rev 1997; 24: 337-44
69. Bakker-Woudenberg IA, ten Kate MT, Stearne-Cullen LE, et al. Efficacy of gentamicin or ceftazidime entrapped in liposomes with prolonged blood circulation and enhanced localization in Klebsiella pneumoniae-infected lung tissue. J Infect Dis 1995; 171: 938-47
70. Allen TM, Moase EH. Therapeutic opportunities for targeted liposomal drug delivery. Adv Drug Del Rev 1996; 21: 117-33
71. MacLean AL, Symonds G, Ward R. Immunoliposomes as targeted delivery vehicles for cancer therapeutics. Int J Oncol 1997; 11: 325-32
72. Lopes de Menezes DE, Pilarski LM, Allen TM. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 1998; 58: 3320-30
73. Kersten GFA, Crommelin DJA. Liposomes and ISCOMS as vaccine formulations. Biochim Biophys Acta 1995; 124 (12): 117-38
74. Huang L, Li S. Liposomal gene delivery: a complex package. Nature Biotech 1997; 15: 620-1
75. Mabato RI, Takakura Y, Hasida M. Nonviral vectors for in vivo gene delivery: physicochemical and pharmacokinetic considerations. Crit Rev Ther Drug Carrier Syst 1997; 14 (2): 133-72
76. Felgner PL. Nonviral strategies for gene therapy. Sci Am 1997 June; 102-10